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HIV infection and its devastating consequences have placed 
an enormous strain on health care resources, those living with/
without HIV, their families and friends. In addition to the broad, 
multi-dimensional impact of this infection, when considering 
kidney disease, HIV has unleashed a new burden of both acute and 
chronic kidney disease (CKD). 
Epidemiology of HIV infec tion
Statistical data from UNAIDS in December 20061 reveal the 
following (Fig. 1):
•    The number of people living with HIV worldwide is estimated 
to be 39.5 million in 2006, 2.6 million more than in 2004 
(Fig. 1). This includes the estimated 4.3 million newly infected 
adults and children. Young people (15 - 24 years of age) accounted 
for 40% of the new infections in 2006. Two-thirds (63%) of all 
adults and children with HIV worldwide live in sub-Saharan 
Africa (24.7 million), with the epicentre in Mozambique, 
Swaziland and South Africa. 
•    In sub-Saharan Africa 13.3 million women over the age of 15 are 
infected with HIV. In this region, women are more likely than 
men to be infected with HIV and they are more likely to be the 
ones caring for people infected with HIV.
•    Of all the known deaths worldwide due to AIDS in 2006, 72% 
occurred in sub-Saharan Africa (2.1 of a total of 2.7 million).  
•    One in 3 adults in Swaziland was living with HIV in 2005 (33%), 
the most intense epidemic in the world.
•    South Africa, in terms of sheer numbers, has one of the world’s 
largest HIV epidemics. Prevalence rates for HIV infection in 
women attending public antenatal clinics were more than one-
third higher (35%) than it had been in 1999. Data collected from 
antenatal clinics suggest that the epidemic has not yet reached 
a plateau. In 2005 there were 5.5 million HIV-infected people 
in South Africa and 240 000 of those were children. In the age 
group 15 - 24 years, young women are 4 times more likely to be 
HIV infected than men.
•    South African mortality data are now revealing the devastating 
impact of the epidemic. Total death rates from all causes in 
South Africa increased by 79% from 1997 to 2004. Death rates 
from natural causes for women aged 25 - 34 years have increased 
five-fold from 1997 to 2004. For males 30 - 44 years of age, death 
rates have more than doubled in the same time period.
HIV infec tion and the kidney
There is a wide spectrum of renal disease that occurs in the course 
of HIV infection. This includes:
•    acute renal failure
•    electrolyte and acid-base disturbances
•    intrinsic renal disease unrelated to HIV itself (diabetes mellitus 
and hypertension)2
•    HIV-associated glomerulonephropathies, which may present 
with either acute or chronic renal failure (Table I)3
•   Side-effects related to treatment of HIV, including those due to:
   •    antiretroviral therapy (tenofovir, in-dinavir)
   •    drugs used to treat infectious com-plications of HIV 
(sulphamethoxazole, acyclovir)
   •    long-term metabolic side-effects of antiretroviral therapy 
(particularly the protease inhibitors).
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Figure 1. Adults and children estimated to be living with HIV in 2006: 39,5 milion (34.1-47.1)
(http://www.unaids.org/en/HIV_data/epi2006/ accessed 11/03/2007)
Fig. 1. Adults an  c ildren estimated to be living with HIV in 2006: 
39.5 million (34.1 - 47.1) (http://www.unaids.org/en/HIV_data/
epi2006/) (accessed 11 March 2007).
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CKD and HIV
With regard to HIV-associated glome-
rulonephropathies, biopsy studies reveal 
varying frequencies of histological patterns.4 
HIV-associated nephropathy (HIVAN) is 
most common, with other lesions accounting 
for one-quarter to one-third of the total. A 
biopsy study at Chris Hani Baragwanath 
Hospital in Soweto showed that HIVAN was 
present in 27% (Fig. 2).5
The above data are based on patients with 
symptomatic renal disease, who are often at 
more advanced stages of their illness. Two 
studies were recently conducted in Kenyan 
and Ugandan outpatient HIV clinics.6,7 
In Kenya, 25% of patients had creatinine 
clearance (Cr Cl) < 90 ml/min, 2% had Cr 
Cl < 60 ml/min and 8% had proteinuria of 
> 1 g/day.6 The Ugandan study showed a 
Cr Cl of < 80 ml/min in 48.5% of patients and 
20% had proteinuria > 100 mg/dl.7 A study 
was conducted in Durban on HIV-positive 
patients screened for proteinuria, including 
microalbuminuria. This is one of a handful 
of studies that have evaluated the prevalence 
and significance of microalbuminuria as 
a marker of early renal disease in HIV. 
Han et al.8 screened 615 patients; 30 renal 
biopsies were performed, 7 for persistent 
microalbuminuria, 23 for overt proteinuria. 
Histology showed HIVAN in 21/30 (72.4%); 
HIVAN + membranous glomerulonephritis 
(GN) 4/30 (13.8%); membranoproliferative 
GN 2/30 (6.9%); interstitial nephritis 
2/30 (6.9%). The prevalence of HIVAN in 
patients with persistent microalbuminuria 
was 85.7%.
 
Renal histology in HIV infection is variable 
and the importance of renal biopsy must 
be emphasised. There is evidence (from 
numerous small studies and case reports) 
that pharmacological interventions for 
HIV focal glomerulosclerosis (FGS)/HIVAN 
delay the progression or prevent the onset of 
renal disease.9 In resource-limited settings, 
such as our own, renal biopsy is often not 
possible, precluding many patients from 
diagnosis and appropriate treatment. For 
these reasons, it is an attractive option to 
develop non-invasive ways of diagnosing 
HIVAN at a primary care level. Thus far, 
no studies have defined non-invasive 
criteria. Certain groups have investigated 
sonographic criteria as predictors of 
HIVAN.10 More recently, it was shown that 
the degree of proteinuria (> 3 g/24 h or a 
protein:creatinine ratio > 3) in combination 
with CD4 count was not predictive of 
HIVAN.11 This is open for further research 
as accurate, non-invasive criteria for the 
diagnosis of HIVAN in resource-limited 






became the most 
rapidly increasing 
cause of ESRD in 
the USA by 1990.
Renal histology 
in HIV infection 
is variable and 
the importance of 
renal biopsy must 
be emphasised.
Table II. Mechanisms of glomerular injury induced by HIV-1 infection
•    Circulating immune complexes involving: 
• viral antigens and host antiviral antibodies 
• endogenous antigens modified by viral injury and host auto-antibodies
•    In situ immune-mediated mechanisms involving viral antigens bound to glomerular 
structures
•    Expression of viral proteins or pathogenic proinflammatory factors in tissue  
inducing the following reactions: 
• cell death through necrosis/apoptosis/cellular dysfunction 
• increased matrix synthesis and/or decreased matrix degradation 
• release of cytokines, chemokines, adhesion molecules, growth factors
•    Direct cytopathogenic effect on glomerular cells with undefined mechanisms
•    Tubulointerstitial injuries due to direct cytopathogenic effects, and secondary media-
tors released in response to glomerular inflammation
•    Haemodynamic disturbance, multiorgan failure
•    Complicating rhabdomyolysis, hepatorenal syndrome
•    Nephrotoxicity of antiviral therapy (occasional)
Fig. 2. HIV-positive patients biopsied between 2003 and 2004.
HIVICK: immune complex deposition disease; Other GNs: other glomerulonephritides; HIVAN: collapsing
glomerulopathy; IgAN: IgA nephropathy; PIGN: post-infectious glomerulonephritis; Other: other (non-
glomerulonephritic) renal disease; MP mesangial proliferative glomerulonephritis.5
Fig. 2. HIV-positiv  patie ts biopsied  
betwee  2003 and 2004.HIVICK: immune 
complex deposition disease; Other GNs: other 
glomerulonephritides; HIVAN: collapsing glo-
merulopathy; IgAN: lgA nephropathy; PIGN: 
post-infectious glomerulonephritis; Other:  
other (non-glomerulonephritic) renal disease; 
MP: mesangial proliferative glomerulonephri-
tis.5
Table I. Spectrum of glomerular disease with HIV
Glomerular pattern   Subtypes 
HIV- focal glomerulosclerosis  Some have described a mixed variant of 
(FGS) ('classic' HIVAN)   HIV-FGS in combination with a prolif- 
     erative glomerulonephritis
HIV- immune complex disease (ICD)  Mesangial proliferative   
(this group often have hepatitis B  Membranoproliferative (type I and III) 
or C coinfection)    Lupus-like    
     Exudative-proliferative   
     Crescentic IgA    
     Membranous
Various glomerulonephropathies  Minimal change    
(this is a heterogenous group with  Immunotactoid    
different aetiologies)   Amyloidosis
HIV-thrombotic thrombocytopenic purpura      
(TTP))/HUS (thrombotic microangiopathy)
Co-morbid disease   Diabetic nephropathy    
     Hypertensive nephrosclerosis  
     Auto-immune disease (e.g. lupus   
     nephritis)
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Various mechanisms for the development 
of glomerular disease in HIV infection have 
been proposed (Table II).12 
HIV-associated 
nephropathy
In the 1980s HIVAN was an uncommon 
cause of end-stage renal disease (ESRD) 
in the USA.13 With improved survival after 
the introduction of antiretroviral therapy, 
HIVAN became the most rapidly increasing 
cause of ESRD in the USA by 1990.13 
There is a marked racial predilection for 
the development of HIVAN, as over 90% 
of patients are black, with a male predo-
minance.2 Statistics in the USA estimate 
the incidence of HIVAN to be 3.5 - 12%.13 If 
this were to be extrapolated to sub-Saharan 
Africa, between 0.9 and 3.1 million people 
would be predicted to have HIVAN. This 
presents a potentially unprecedented burden 
of CKD. At present, HIV-positive patients 
with end-stage renal failure (ESRF) are rarely 
offered chronic dialysis or transplantation 
in the public health sector of South Africa. 
This poses daunting logistical, financial and 
ethical issues for clinical nephrologists. 
His topathology of HIVAN 
(Fig. 3)
HIVAN is characterised by a specific 
constellation of pathological findings that 
involve glomerular, tubular and interstitial 
compartments of the kidney:14 
•    focal glomerulosclerosis with prominent 
collapse of the glomerular tuft
•    tubular dilatation, flattening of tubular 
epithelial cells, microcysts
•    lymphocytic infiltrates of interstitium 
with patchy oedema and/or interstitial 
fibrosis
•    endothelial tubuloreticular inclusions 
(on electron microscopy), thought to be 
related to increased interferon levels, are 
characteristic but not pathognomic of 
HIVAN
•    increased mesangial matrix, hyperplasia of 
mesangial cells may be seen but whether 




There have been no prospective randomised 
controlled studies with any form of therapy 
for HIVAN to date. Therapies used in the 
treatment of HIVAN include those directed 
at the kidney damage from HIV infection, 
which have included corticosteroids, 
cyclosporine and antiretroviral therapy. The 
other focus of treatment involves agents 
for the treatment of proteinuria such as 
angiotensin-converting enzyme inhibitors 
(ACE-I), dyslipidaemias (if nephrotic), and 
co-morbid disease (hypertension). Renal 
replacement therapy (RRT) options for 
patients who have reached ESRD include 
haemo- or peritoneal dialysis and renal 
transplantation. 
Corticosteroids
In various studies, patients with HIVAN 
treated with prednisone experienced 
an improvement in renal function and 
reduction of proteinuria but complications 
such as relapse after steroid withdrawal, 
opportunistic infections, psychosis and 
gastrointestinal bleeding were relatively 
common.9 Because these studies have no 
long-term follow-up, are small in size and 
not randomised, no clear conclusions can be 
made regarding their use in HIVAN. Most 
clinicians would not treat biopsy-proven 
HIVAN with corticosteroids since the 
availability of antiretroviral therapy.
Angiotensin-converting enzyme 
inhibitors (ACE-I) 
Small studies have shown benefit with ACE-
I such as captopril and fosinopril.15,16 The 
beneficial effects of ACE-I may be related 
to improved renal haemodynamics, reduced 
proteinuria or cytokine modulation.17 The 
effects of angiotensin-2 receptor blockers 
(ARBs) in the treatment of HIVAN are 
unknown, just as the effects of ACE-I or 
ARBs in the treatment of HIV-associated 
renal disease other than HIVAN are 
unknown.
Cyclosporine
The effectiveness of cyclosporine in inducing 
remission of proteinuria was reported in 
children with HIVAN.18 There are no studies 
evaluating the role of cyclosporine in adults 
with HIVAN. 
Highly active antiretroviral therapy
Antiretroviral therapy appears to be a 
logical choice in the management of HIV-
associated renal disease. There appears to be 
a more beneficial effect of triple combination 
over zidovudine monotherapy.19 Regimens 
containing protease inhibitors have been 
shown to be associated with significant 
slowing of the decline in creatinine clearance. 
Whether this effect is superior to the effect 
of other classes of antiretroviral therapy is 
unknown.19
Screening for renal 
disease in HIV
The extent of the HIV epidemic, its associated 
burden of CKD in sub-Saharan Africa, 
coupled with the cost of RRT in a resource-
limited setting, make this a very difficult 
problem. The stark reality at present in South 
Africa is that most people with ESRD and 
HIV die. Some have limited access to dialysis 
(mostly in the private sector), and this group 
of patients are not offered cadaveric kidney 
transplantation. Currently, most clinicians 
deal with advanced stages of CKD in HIV, 
and prevention or early detection of renal 
disease in this population is neglected. 
This is partly because patients present 
late, but also because there has been very 
little research globally and in sub-Saharan 
Africa on the impact of interventions (e.g. 
antiretrovirals, ACE-I) on the progression 
of CKD in this population. To address 
this, we require local research and a firm 
commitment at national level as the platform 
from which a clear strategy for management 
from primary to tertiary levels of health care 
can be implemented. Primary health care 
practitioners need a working system in place 
for referral of patients with abnormalities on 
screening. Referral centres require resources 
for appropriate investigation and treatment 
of patients with confirmed CKD. 
Currently, there are no guidelines in South 
Africa for screening of HIV-infected 
individuals for CKD. Urinary screening 
The stark reality 
at present in 
South Africa is 
that most people 
with ESRD and HIV 
die.
Fig. 3. Typical histopathological findings of HIVAN. Periodic acid-Schiff staining demonstrates focal
segmental glomerulosclerosis (arrowhead) with collapse of the glomerular tuft (arrow), tubular microcystic
disease (*), interstitial lymphocytic infiltration and interstitial fibrosis. Magnification x 200.18
Fig. 3. Typical histopat ological findings of 
HIVAN. Periodic acid-Schiff staining  
demonstrates focal segmental glomerulosclero-
sis (arrowhead) with collapse of the glomerular 
tuft (arrow), tubular microcystic disease(✳), 
interstitial lymphocytic infiltration and inter-
stitial fibrosis. Magnification x 200.13
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of new or ‘at risk’ patients for the presence 
of renal disease in antiretroviral clinics in 
South Africa is unfortunately not considered 
standard of care. The care of patients with CKD 
and HIV unfortunately remains in the hands 
of a few interested clinicians, which is not 
sustainable. The Infectious Diseases Society 
of America (IDSA) published guidelines to 
this effect in 2005.20 Their recommendation 
is that all individuals be assessed for kidney 
disease at the time of diagnosis of HIV 
infection with a screening urinalysis for 
proteinuria and a calculated estimate of 
renal function. This allows for, detection 
of renal disease and dose  adjustment of 
antiretrovirals and other commonly used 
drugs in HIV infection, such as acyclovir, 
trimethoprim-sulphamethoxazole, and anti-
TB medication. A screening algorithm has 
been suggested by the IDSA and is depicted 
in Fig. 4. The IDSA criteria for those at ‘high 
risk’ for development of proteinuric renal 
disease are: African Americans, CD4 counts 
< 200 cells/mm3, HIV RNA levels > 4 000 
copies/ml, patients with diabetes mellitus, 
hypertension or hepatitis C co-infection 
(although chronic hepatitis C infection is 
not very common in South Africa). Most 
patients in South African antiretroviral 
clinics would fulfil these criteria based on 
WHO staging and CD4 count. Ideally, the 
programme for prevention of CKD in HIV 
would work best if coupled to an early 
screening programme for HIV testing, 
where the shift is on diagnosing HIV in 
early stages of infection, when most are still 
asymptomatic. At present, the screening 
algorithm could be utilised as a template for 
clinicians. We would however suggest that, 
as a matter of urgency, a working committee 
be established for drawing up national 
guidelines for the screening, detection 
and management of CKD in HIV-infected 
individuals in South Africa. 
Conclusion
There is a critical role for local research, in the 
form of prospective, randomised, controlled 
trials on the impact of early diagnosis and 
treatment of HIVAN and its effect on 
outcome. It is proposed that a working group 
for the establishment of guidelines for the 
screening, early detection and management 
of renal disease in HIV-infected individuals 
in South Africa is established.
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In a nutshell 
•    Sub-Saharan Africa is at the epicentre of the HIV pandemic.
•    Acute and chronic kidney disease is common in the course of HIV infection.
•    There is a huge projected burden of CKD as a result of HIV in sub-Saharan Africa, for 
which we do not have the resources to cope.
•    At present, most people with ESRD and HIV are not offered renal replacement therapy 
(dialysis and transplantation).
•    More emphasis needs to be placed on screening and prevention of CKD in HIV.
•    A screening and prevention programme for CKD in HIV needs to be devised and 
implemented as a matter of urgency.
•    Appropriate and well-designed research from the sub-Saharan region needs to be 
done to determine the effect of interventions on the progression of CKD in HIV.
CKD and HIV
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